Tharimmune, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a THAR research report →
Companywww.tharimmune.com
Tharimmune, Inc. , a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
- CEO
- Mark Wendland
- IPO
- 2022
- Employees
- 2
- HQ
- Bridgewater, NJ, US
Price Chart
Valuation
- Market Cap
- $139.94M
- P/E
- -8.36
- P/S
- 0.00
- P/B
- 1.44
- EV/EBITDA
- -1.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.93%
- ROIC
- -8.26%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-35,916,250 · -194.45%
- EPS
- $-1.12 · 88.10%
- Op Income
- $-20,106,066
- FCF YoY
- -47.94%
Performance & Tape
- 52W High
- $9.08
- 52W Low
- $0.95
- 50D MA
- $3.47
- 200D MA
- $2.73
- Beta
- 1.45
- Avg Volume
- 850.30K
Get TickerSpark's AI analysis on THAR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our THAR Coverage
We haven't published any research on THAR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate THAR Report →